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Abstract
This study aims to identify novel markers for gestational diabetes (GDM) in the biochemical profile of maternal urine using
NMR metabolomics. It also catalogs the general effects of pregnancy and delivery on the urine profile. Urine samples were
collected at three time points (visit V1: gestational week 8–20; V2: week 2862; V3:10–16 weeks post partum) from
participants in the STORK Groruddalen program, a prospective, multiethnic cohort study of 823 healthy, pregnant women in
Oslo, Norway, and analyzed using 1H-NMR spectroscopy. Metabolites were identified and quantified where possible. PCA,
PLS-DA and univariate statistics were applied and found substantial differences between the time points, dominated by a
steady increase of urinary lactose concentrations, and an increase during pregnancy and subsequent dramatic reduction of
several unidentified NMR signals between 0.5 and 1.1 ppm. Multivariate methods could not reliably identify GDM cases
based on the WHO or graded criteria based on IADPSG definitions, indicating that the pattern of urinary metabolites above
micromolar concentrations is not influenced strongly and consistently enough by the disease. However, univariate analysis
suggests elevated mean citrate concentrations with increasing hyperglycemia. Multivariate classification with respect to
ethnic background produced weak but statistically significant models. These results suggest that although NMR-based
metabolomics can monitor changes in the urinary excretion profile of pregnant women, it may not be a prudent choice for
the study of GDM.
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Introduction
Type 2 diabetes (T2DM) is one of the most challenging health
problems in this century, and its prevalence is rising – in a
worldwide perspective, it is projected that by 2030 more than 500
million people will suffer from diabetes. The escalating costs
threaten the health care system of any nation, and complications
associated with the disease are a major cause of disability, reduced
quality of life, and death. [1,2] Gestational diabetes mellitus
(GDM) shares pathophysiological similarities with T2DM and
accordingly, along with the increase of obesity and T2DM in
women of reproductive age, an increase of GDM is observed. [3,4]
GDM is defined as any degree of glucose intolerance with onset or
first recognition during pregnancy and increases the risk of adverse
pregnancy outcomes, and future development of T2DM in both
the mothers and their offspring. [4–7] Fortunately, short-term
pregnancy outcomes can be improved and the risk of later T2DM
reduced through lifestyle intervention, turning the prevention of
GDM into a crucial opportunity to positively impact the life and
health of mother and child. [3,8,9].
The STORK Groruddalen research program [10–12] aims to
improve the identification of pregnancies at high risk for GDM
and other complications in order to reduce adverse short and long-
term outcomes for mothers and offspring. The name of the
program refers to the bird’s symbolic function and the residential
area of the study participants, the ethnically highly diverse
Groruddalen region of Oslo, Norway. As part of this larger effort,
and since GDM is a disorder of the metabolism, NMR
metabolomics was undertaken to characterize changes in the
urinary profile during and after pregnancy, and to search in these
profiles for novel biomarkers for GDM. In the current literature
on metabolic adaptations in pregnancy there is a marked focus on
glucose and lipid metabolism, and most reports are concerned
with measurements on maternal blood. [13–15] Much less is
published about the urinary excretion profile, but it is known that
the glomerular filtration rate increases in pregnancy, and that
especially the excretion of amino acids is elevated, particularly
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when approaching term. Glucose and other sugars may also be
excreted at elevated levels, but not only in conjunction with GDM.
[16,17] The current diagnostic protocols for GDM rely on
detecting elevated glucose levels in blood, often only late in the
second trimester. [18,19] Therefore, finding substances (or
patterns thereof) non-invasively in the urine profiles that could
predict the development of GDM before it manifests itself would
provide a highly desirable improvement, and the relatively young
discipline of metabolomics claims this to be its strength.
Metabolomics, unlike more compound-specific analyses of
clinical chemistry, is an approach that tries to model changes in
broad profiles of metabolites and relate them to health and disease
states. [20] The most commonly used profiling platforms are mass
spectrometry (MS) coupled with gas or liquid chromatography and
a range of different ionization techniques, or nuclear magnetic
resonance spectroscopy (NMR). [21] In the present study, 1H-
NMR spectroscopy was chosen because it offers the possibility of
measuring a large number of small metabolites with a reasonable
sensitivity in the micromolar range [21] while conveniently
requiring only little sample preparation and acquisition times of
typically not more than a few minutes. [22] In studies involving
large sets of spectra the analytical variation of results was shown to
be as small as 2%, reflecting an impressive degree of reproduc-
ibility. [23].
Metabolomics has been successfully applied to the study of a
wide range of diseases in humans and animal models, from type 1
and 2 diabetes to autism, asthma and cancer. [24–27] In
pregnancy research there has been a focus on preeclampsia and
other distinct complications [28], and at least one exploratory
study also suggested potential biomarkers for GDM. [29].
In this study we have tested whether urine NMR metabolomics
can find biomarkers that identify women at risk of developing
GDM in a large, multiethnic prospective cohort study. The
analysis yielded a comprehensive overview of urinary metabolite
concentrations during and after pregnancy which we report as a
secondary objective. We have also studied the influence of ethnic
background on the metabolite profile.
Materials and Methods
Study Population and Sample Collection
The STORK Groruddalen project has been described in detail
previously. [10] Briefly, 823 healthy, pregnant women, 59% from
ethnic minorities, attending the Child Health Clinics in Gror-
uddalen, Oslo, between 2008 and 2010 were included in the study.
Women with diabetes diagnosed before pregnancy were excluded
in order to particularly study GDM. The participation rate was
74%, and the participating women were found representative of
the main ethnic groups. The participants were on average (6 SD)
29.9 (64.8) years of age, had a prepregnant BMI of 24.6 (64.8)
and were mostly nulli- or uniparous (45.7% and 34.4%,
respectively). Previous publications discusses the characteristics
and representativeness of the cohort in detail, with a particular
focus on ethnic background. [10,11].
Fasting morning midstream clean-catch urine samples were
collected at three visits (V1: gestational week 8–20; V2: week
2862; V3:10–16 weeks post partum), and routine tests for nitrite,
proteinuria and glucosuria were performed using dipsticks. The
remainder was aliquoted and stored at 280uC. Albumin and
creatinine concentrations were determined using one of each
samples’ aliquots while another was reserved for the NMR analysis
described in the present article. At visit V2 a 75 g oral glucose
tolerance test (OGTT) was performed, measuring fasting (FPG)
and 2-hour venous plasma glucose (2-h PG). The participants who
were diagnosed with GDM according to WHO definitions (see
below), the current standard in clinical practice in Norway,
received lifestyle advice and were remitted to their GP or specialist
care for follow-up, where few required insulin. Note that this
would only influence a small number of observations at the last
visit V3, since V1 and V2 were completed before the diagnosis.
Definition of Endpoints
GDM was diagnosed independently according to two separate
sets of criteria: The first set are the criteria of the World Health
Organization (WHO) which define GDM as FPG $7.0 or 2-h PG
$7.8mmol/L. [19] The second, more finely graded criteria define
participants with FPG ,5.1 and 2-h PG ,8.5mmol/L as healthy
(introducing the abbreviation G0), those above at least one of the
limits as having GDM with mild hyperglycemia (G1), and finally
those with FPG $5.8 mmol/L or 2-h PG $11.1 mmol/L as
GDM with pronounced hyperglycemia (G2). These latter criteria
are based on the recommendations by the International Associ-
ation of Diabetes and Pregnancy Study Groups (IADPSG).
[11,18,30].
The WHO criteria identified 13% of the STORK participants
as GDM cases. The graded criteria find a GDM prevalence of
32%, further subdivided into 26% with mild (G1) and 6% with
more pronounced hyperglycemia (G2).
Ethnic origin was defined by country of birth of the participant
or her mother, whichever was more relevant [10], and categorized
into Europe (n= 379; including North Americans of European
descent), South Asia (n = 200), East Asia (n = 44), Middle East
(n = 126; including Central Asia and North Africa), Sub-Saharan
Africa (n = 62; mainly Somalia) and South America (n = 12).
Ethics
The women were given oral and written information, available
in eight languages, when attending the Child Health Clinics.
Participation was based on written consent. The Regional Ethics
committee and The Norwegian Data Inspectorate have approved
the study protocol of the STORK Groruddalen research program.
The Norwegian Directorate of Health accepted the storage of
biological material. [10].
Acquisition of 1H NMR Spectra
Urine samples were thawed, and 900 ml of sample were buffered
with 100 ml of a KH2PO4/KOH solution at pH 7.4 in pure D20,
containing NaN3 to inhibit bacterial growth and Trimethylsilyl
propanoic acid (TSP) as a frequency and concentration reference.
The buffered samples were centrifuged at 13,400 g and 4uC for 5
minutes, and 600 ml were transferred to 5 mm NMR tubes.
Proton NMR spectra were acquired at 300.0 K on a Bruker AV
600 spectrometer equipped with a TCI cryoprobe and an
automatic sample changer. Of each sample 32 scans were
collected into 64k data points using the Bruker ‘‘noesygppr1d’’
sequence with a spectral width of 20.6 ppm, 2.65 s acquisition
time and a 4 s relaxation delay. An exponential line broadening of
0.3 Hz was applied and the Fourier-transformed spectra were
referenced to the TSP signal. Additionally, one single-scan,
pseudo-2D J-resolved spectrum was acquired per sample using
the ‘‘jresgpprqf’’ sequence.
Of a selection of representative samples, two-dimensional
spectra were acquired in order to facilitate compound identifica-
tion. [31].
Eventually, after accounting for missing samples and removing
a small number of low-quality spectra, a total of 1,911 urine
profiles from 790 of the 823 participants (667, 671 and 573 from
visits V1, V2 and V3, respectively) were eligible for further
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analysis. Among these were 572 matched pairs between visits V1
and V2, 509 between V2 and V3, and 494 between V1 and V3.
There were 454 complete series with high-quality spectra from all
three visits.
Spectral Processing and Analysis
All spectra were preprocessed with an in-house program written
in GNU Octave [32], which first performed a zero-order phase
correction on the TSP signal and a first-order correction on the
aromatic region of the spectrum, and then subtracted separate
linear baselines from the regions up- and downfield of the water
artifact. The latter is necessary because the AV 600 instrument
lacks an option that produces flat baselines. Finally, the urine
spectra were re-referenced to the TSP signal at 0.0 ppm and
clipped to the spectral range between -0.5 and 9.0 ppm.
Further processing and analysis was carried out with the
statistics environment R. [33] The spectra were first normalized to
the area under the TSP signal. An adaptive, nonlinear baseline
was then subtracted using the Barkauskas-Xi-Rocke (BXR)
algorithm implemented in the R package ‘‘FTICRMS’’. [34,35]
The water artifact, the TSP signal and the urea region of the
spectra were subsequently deleted.
Metabolites were identified by using published literature [36–
39] and the Human Metabolome Database (HMDB) [40,41] and
were quantified by comparing the area under their respective
signals with that of TSP. A number of consistent but unidentified
signals were also measured, but their concentrations are conse-
quently relative to an unknown number of contributing protons
and therefore reported in arbitrary units. Together, these resulted
in a set of ca. 50 concentration variables (or quasi-concentrations,
in the case of the unknowns) per sample – a compressed, noise-
reduced representation of its spectrum.
Finally, both the spectra and the concentration variables were
individually normalized to the absolute creatinine concentration of
the respective urine sample. As an internal consistency check, the
creatinine concentrations as determined by NMR were compared
with measurements performed on a Roche Modular (Roche
Diagnostics Ltd., Burgess Hill, UK) at the Central Laboratory,
Oslo University Hospital, Aker, and found to be in good
agreement (R2.95%). Citrate concentrations of a small number
of representative samples were also validated against enzymatic
measurements [42] at the same laboratory (R2.98%). Finally, the
distribution of the concentration variables proved to be right-
tailed. Therefore, in most analyses the variables were log-
transformed, and the results transformed back as necessary.
The urine spectra and the concentration variables were then
subjected to principal component analysis (PCA, implemented in
the R package ‘‘pcaMethods’’ [43]) in order to survey the most
defining variations in the spectra and to search for outliers. Unit-
variance scaling was applied in order to amplify the contribution
of small signals, i.e. lower-concentration metabolites. The PCA
scores plots were color-coded according to the three visits.
To investigate the relations between the spectra and given
endpoints, i.e. classifications by visit, diagnosis of GDM, or ethnic
background, partial least-squares regression (PLS, using the R
package ‘‘pls’’ [44]) was employed in the form of discriminant
analysis (PLS-DA). A simple vector of class codes was used when
two classes were involved, and a dummy matrix when more than
two classes were to be modeled. The analyses were carried out
using unit-variance scaling of the variables, and segment-wise cross
validation to avoid overfitting. The final models were evaluated by
the parameters R2, describing the goodness of fit, and more
importantly Q2, estimating the predictive power after cross
validation. Consequently, the ratio Q2/R2 describes the reliability
of a model under cross-validation – whether it performs equally
well on new input as on the data it was constructed from. A ratio
below 0.5 would raise suspicions of overfitting, i.e. modeling noise
in absence of systematic variations, while a model with a Q2/R2
ratio above 0.8 would be considered consistent and valid.
Additionally, the number of misclassifications (NMC) of the
PLS-DA models was calculated based on 500 repetitions of the
cross validation as an alternative measure of reliability and
compared to the distribution of randomly permutated classifica-
tions. [45].
Univariate statistical summaries and tests were performed based
on the creatinine-normalized, log-transformed concentration
variables to support and expand upon any multivariate modeling.
In particular, median concentrations and the interquartile range
(IQR) of their distributions were calculated for all classes and
groups encountered throughout this article, and presented in
tables. Two-sample t-tests (or k-sample ANOVAs, as appropriate)
were carried out to estimate the significance of group differences.
As a special case, when comparing the progression of matched
pairs of samples between the three visits, individual fold-change
factors could be computed from the log differences, and paired
instead of two-sample t-test were appropriate. All p-values are
reported without correction for multiple testing.
Results
Difference between Visits
PCA of the urine spectra produced a weak clustering of samples
from the three visits, respectively, but suffered from noise due to
e.g. positional variations of compound resonances (data not
shown). A PCA of the creatinine-normalized, log-transformed
concentration variables, shown in Figure 1, yielded a much clearer
picture. There was a certain overlap between the samples from the
first and second visit, but in particular the second and third visits
were well separated.
The classification potential was demonstrated by PLS-DA on a
dummy matrix of all three visits simultaneously: Using 5
components, the model based on the concentration variables
correctly classified 86% of the samples compared to 31% in the
permutation test. The model based on the spectra, using 7
components, achieved a very similar 85% correct classification.
In order to track the specific changes between the visits, pairwise
PLS-DA was carried out using both the spectra and the
concentration values. The results of the latter are shown in
Table 1. As in the PCAs, the most substantial difference happened
between visit V2 (late pregnancy) and V3 (post partum), driven
primarily by the dramatic reduction of the as yet unidentified
compound(s) with NMR resonances at 0.55, 0.62 and 0.78 ppm
(Fig. 2), as well as 1.08 and 1.11 ppm. A scatter plot of one of these
signals against lactose concentrations (Fig. 3) closely mirrored the
clustering found in Fig. 1 using PCA.
Finally, univariate statistics were employed to quantify the
changes. Table 2 presents the group-wise median urinary
concentrations (with IQR) of selected compounds and unidentified
substances relative to the creatinine concentration at the three
visits, along with the mean fold change between the visits
calculated at the individual level.
Gestational Diabetes
The multivariate analysis with respect to GDM yielded few
positive results. All Q2 were negative for both sets of diagnostic
criteria, with the following exceptions: PLS-DA of the concentra-
tion variables according to the WHO criteria resulted in barely
positive Q2= 2% at visit V1, with the unidentified signal at
Gestational Diabetes, Urine Profile in Pregnancy
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Figure 1. Urine samples distinguish time points during and after pregnancy. PCA scores plot from creatinine-normalized, log-transformed
concentration variables, showing the first and second principal component, i.e. the two linear combinations of the original variables that contain the
largest and second-largest overall variation (24% and 10%, respectively). Note the clustering of samples from the three visits (V1, gestational week 8–
20: red circles; V2, week 26–30: green triangles; and V3, 10–16 weeks post partum: filled blue circles). Red lines connect corresponding samples from
visits V1 and V2; blue lines from V2 and V3. Solid black lines represent the density of the scores from the three visits. The overlap between visit V2 and
V3 appears to be the smallest.
doi:10.1371/journal.pone.0052399.g001
Figure 2. Development of four influential NMR signals over time. Proton NMR spectra of all three urine samples from one healthy
participant, showing the region between 0.5 and 0.9 ppm; normalized to the creatinine concentration, BXR baseline correction not yet applied in
order to preserve the shape of the broader peaks. The four highlighted signals increase from visit V1 (red line, gest. week 8–20) to V2 (green line, gest.
week 26–30) and then disappear at V3 (blue line, 10–16 weeks post partum).
doi:10.1371/journal.pone.0052399.g002
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1.11 ppm and citrate contributing most to the loading weights.
Using a dummy matrix of the graded criteria, PLS-DA yielded
Q2= 2% for the pronounced hyperglycemia class G2 at visit V2,
involving citrate, glucose and the unidentified signal at 1.08 ppm.
A subsequent univariate analysis supported and quantified these
findings. Table 3 shows compounds that were significantly altered
at visit V1 and V2, respectively, using t-tests with respect to the
two classes of the first, i.e. WHO criteria, along with their median
concentrations in said classes. Table 4 shows the same for
ANOVA with respect to the three classes of the second, i.e. graded
criteria. No significant differences were observed at visit V3 using
either diagnostic criteria.
Expanding on the differences observed for the graded classes,
Figure 4 illustrates the development of urine citrate concentration
in the three classes during and after pregnancy, presenting the
class-wise mean concentration relative to creatinine concentration.
Figure 3. Lactose and an unidentified compound dominate the urinary changes during pregnancy. Scatter plot of concentrations
(relative to creatinine concentration; log axes) of lactose and an unidentified substance with an NMR signal at 0.62 ppm. Red circles, green triangles
and filled blue circles for visit V1 (gestational week 8–20), V2 (gestational week 26–30) and V3 (10–16 weeks post partum), respectively. Note how
these two compounds alone reproduce a clustering similar to that in Fig. 1.
doi:10.1371/journal.pone.0052399.g003
Table 1. Validation results and most influential compounds of pairwise PLS-DA models from the log-transformed concentration
variables with respect to the three visits.
Visit
Q2 and R2 values of the
first 3 componentsa
NMC at 5 components
and permutation testb Involved compoundsc
V1 R V2 0.526, 0.663, 0.679/0.534, 0.676,
0.700
89.3 (84.0–93.8)/662 (625–695) Unknown, 0.62 ppmq; Unknown, 0.78 ppmq; Alanineq; Glycineq;
Lactoseq
V2 R V3 0.791, 0.868, 0.883/0.794, 0.873,
0.891
9.0 (8.0–10.0)/607 (581–633) Unknown, 0.62 ppmQ; Unknown, 0.78 ppmQ; AlanineQ; GlycineQ;
Lactoseq
V1 R V3 0.690, 0.782, 0.803/0.695, 0.788,
0.815
35.5 (32.3–39.0)/601 (578–627) Unknown, 0.62 ppmQ; Unknown, 0.78 ppmQ; AlanineQ; GlycineQ;
Lactoseq
aA high ratio between Q2 and R2 confirms the validity of the models.
bThe number of misclassifications (NMC) of the PLS-DA models relative to the random result from permutation testing serves as a performance estimate; 95% CI of the
estimates in parentheses.
cSpectral signals that could not be assigned to known metabolites are referred to as ‘‘Unknown’’, along with the locations of their NMR signals. Arrows denote relative
increase or decrease between visits. See also Table 2 and Fig. 2.
doi:10.1371/journal.pone.0052399.t001
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Table 2. Median concentrations (IQR) of profiled compounds relative to creatinine concentration at the three visits, and patient-
wise fold-change between visits.
Median concentrationa (IQR) [mM/mM Creatinine] Rel. individual FCa (t-test p-value)
Compound Visit V1b (,20 wk) Visit V2b (28 wk) Visit V3b (3 mo p.p.) V1 R V2 V2 R V3
Ureac,d 2.5 (1.9–3.3) 2.4 (1.9–3.1) 2.6 (2–3.3) 21.01 (0.64) 1.07 (0.0025)
Unknown multiplet, 0.55 ppmx,d 2.3 (1.9–2.9) 4.9 (4.1–5.9) 1.7 (1.3–2.2) 2.12 (7e-200) 22.88 (2.7e-194)
Unknown multiplet, 0.62 ppmx,d 4.2 (3.4–5.3) 9.4 (7.9–11) 1.8 (1.4–2.3) 2.2 (1.4e-219) 25.14 (2.8e-283)
Unknown multiplet, 0.78 ppmx,e 0.2 (0.091–0.34) 1.2 (0.92–1.6) 0.026 (0–0.084) 6.11 (1.4e-151) 221.8 (1e-125)
Unknown multiplet, 0.90 ppmx,e 0.28 (0–1.1) 2.6 (1.3–4.4) 0 (0–0.3) 3.42 (1.1e-42) 24.35 (8e-24)
Unknown doublet, 0.75 ppmx,e 0.047 (0.0085–0.15) 0.04 (0.006–0.13) 0.055 (0.01–0.17) 21.12 (0.22) 1.45 (0.00027)
Valine 0.0059 (0.004–0.008) 0.006 (0.004–0.008) 0.0041 (0.003–0.006) 21.02 (0.29) 21.45 (2.5e-34)
Leucine 0.004 (0.003–0.005) 0.0045 (0.003–0.006) 0.0025 (0.002–0.004) 1.12 (2.1e-11) 21.83 (8.2e-89)
Unknown doublet, 1.08 ppmx 3.5 (2.3–5) 5.4 (3.6–8.1) 2.1 (1.4–3.1) 1.61 (5.9e-68) 22.63 (1.4e-106)
Unknown doublet, 1.11 ppmx 11 (7.5–16) 19 (14–25) 2.9 (1.9–4.4) 1.78 (3.1e-114) 26.66 (1.2e-231)
3-Aminoisobutyratee 0.0098 (0.004–0.022) 0.011 (0.0041–0.024) 0.008 (0.003–0.019) 1.08 (0.14) 21.28 (0.00018)
Unknown doublet, 1.24 ppmx,e 2.9 (2.2–4) 4.4 (3–6.2) 3.2 (2.3–4.5) 1.43 (1.6e-38) 21.33 (2.8e-20)
Unknown doublet, 1.26 ppmx,e 1.3 (0.78–1.9) 1.9 (1.3–2.8) 0.88 (0.41–1.4) 1.55 (1.2e-40) 22.31 (6.2e-65)
3-Hydroxyisovaleratee 0.0092 (0.007–0.012) 0.011 (0.0084–0.014) 0.0054 (0.004–0.007) 1.2 (5.8e-28) 22.1 (7.9e-145)
2-Hydroxyisobutyrate 0.0071 (0.006–0.008) 0.0076 (0.006–0.009) 0.0054 (0.004–0.006) 1.11 (1.0e-14) 21.44 (2.5e-87)
comb. Lactate/Threoninex 29 (20–43) 56 (39–83) 8.7 (5.8–13) 1.89 (1.6e-89) 26.3 (2.6e-202)
Alanine 0.04 (0.029–0.054) 0.065 (0.046–0.09) 0.02 (0.015–0.028) 1.62 (1.7e-84) 23.22 (1.5e-191)
Lysinee 0.02 (0.011–0.034) 0.016 (0.009–0.026) 0.0093 (0.005–0.016) 21.26 (4.7e-08) 21.64 (6.8e-23)
Acetaminophen metabolitesx,e 9.3 (6.5–14) 10 (6.7–14) 5.8 (3.5–9.4) 1.04 (0.27) 21.56 (1.1e-14)
Acetone 0.003 (0.002–0.005) 0.004 (0.003–0.006) 0.003 (0.002–0.005) 1.1 (0.38) 21.09 (0.49)
N-Acetylglutamine 0.055 (0.04–0.08) 0.048 (0.03–0.07) 0.07 (0.045–0.09) 21.29 (1.5e-13) 1.6 (5.6e-34)
Unknown singlet, 2.35 ppmx 17 (9.4–28) 16 (8.1–26) 21 (11–31) 21.13 (0.00072) 1.3 (3.7e-11)
Citrate 0.24 (0.18–0.3) 0.25 (0.18–0.32) 0.15 (0.1–0.21) 1.03 (0.077) 21.64 (2.7e-56)
Dimethylamine 0.041 (0.037–0.046) 0.047 (0.043–0.052) 0.042 (0.038–0.048) 1.14 (1.9e-18) 21.08 (1.8e-06)
Unknown singlet, 2.78 ppmx 3 (2.4–3.9) 2.9 (2.4–3.9) 3.6 (2.9–4.8) 21.01 (0.68) 1.26 (6.8e-17)
Trimethylamine N-oxide 0.038 (0.025–0.064) 0.037 (0.022–0.064) 0.041 (0.027–0.073) 21.12 (0.019) 1.22 (0.00055)
Glycine 0.24 (0.17–0.36) 0.32 (0.23–0.45) 0.11 (0.056–0.18) 1.32 (3.9e-41) 23.06 (6.6e-118)
Creatine 0.079 (0.033–0.15) 0.086 (0.042–0.16) 0.05 (0.021–0.13) 1.16 (0.00022) 21.56 (2.7e-17)
Creatininef [abs. mM] 10 (7.3–14) 8.5 (6.3–12) 12 (8.8–16) 21.19 (8.6e-13) 1.33 (1.5e-25)
Trigonelline 0.011 (0.0066–0.018) 0.012 (0.0068–0.023) 0.014 (0.0073–0.027) 1.11 (0.017) 1.14 (0.012)
Lactose 0.04 (0.025–0.06) 0.1 (0.073–0.14) 0.24 (0.14–0.39) 2.47 (6.4e-122) 2.11 (2.8e-51)
1-Methylnicotinamide 0.009 (0.007–0.012) 0.013 (0.0093–0.017) 0.0053 (0.003–0.008) 1.41 (4.3e-42) 22.58 (5.4e-111)
Unknown singlet, 4.51 ppmx,e 0 (0–0.062) 0 (0–0.25) 0 (0–0.17) 1.1 (0.66) 21.41 (0.14)
Ascorbatee 0.006 (0.004–0.011) 0.01 (0.006–0.016) 0.006 (0.004–0.011) 1.58 (9.6e-14) 21.47 (6.9e-10)
Glucose 0.1 (0.079–0.13) 0.14 (0.11–0.18) 0.079 (0.064–0.11) 1.39 (6.3e-35) 21.77 (2.3e-64)
Acetaminophen glucuronidee 0.033 (0.023–0.046) 0.039 (0.028–0.053) 0.029 (0.022–0.043) 1.18 (3.9e-08) 21.18 (1.3e-05)
Unknown multiplet, 5.02 ppmx,e 0.89 (0.43–1.8) 0.93 (0.46–1.8) 1 (0.54–1.9) 1.07 (0.18) 1.12 (0.044)
Unknown doublet, 5.08 ppmx,e 0.089 (0–0.26) 0.084 (0–0.29) 0.12 (0–0.29) 21.02 (0.8) 1.02 (0.87)
Unknown doublet, 5.20 ppmx 1.8 (1.3–2.5) 2.5 (1.9–3.6) 1.2 (0.86–1.7) 1.38 (6.3e-34) 22.1 (1.2e-75)
Sugar doublets, 5.23 ppmx 7.8 (6.1–10) 16 (12–20) 22 (15–33) 1.98 (4.6e-120) 1.27 (3.9e-11)
Unknown doublet, 5.30 ppmx,e 0.53 (0.34–0.81) 1.2 (0.71–1.7) 0.66 (0.47–0.93) 1.99 (7.6e-78) 21.61 (1.1e-45)
Unknown doublet, 5.42 ppmx,e 0.29 (0.077–0.83) 0.52 (0.18–1.2) 0.42 (0.12–1.1) 1.56 (3.3e-07) 21.12 (0.22)
1,6-Anhydroglucosee 0.003 (0.001–0.006) 0.005 (0.002–0.01) 0.003 (0.002–0.007) 1.64 (1.1e-14) 21.4 (2.3e-08)
Unknown doublet, 6.58 ppmx,e 0.015 (0–0.17) 0.013 (0–0.18) 0.027 (0–0.22) 1.0 (0.99) 1.08 (0.59)
4-Hydroxyphenylacetate 0.009 (0.007–0.01) 0.01 (0.08–0.014) 0.01 (0.08–0.014) 1.07 (0.028) 21.01 (0.72)
Tyrosine 0.012 (0.008–0.016) 0.013 (0.0092–0.019) 0.0051 (0.003–0.008) 1.16 (1e-12) 22.9 (1.2e-91)
N-Phenylacetylglycineg 0.074 (0.047–0.11) 0.065 (0.038–0.099) 0.09 (0.054–0.13) 21.15 (0.00018) 1.37 (3e-14)
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The insets show the mean values of the individual fold-changes
between the visits of each patient. Clearly, the GDM patients with
more pronounced hyperglycemia (G2) exhibited a stronger
increase during pregnancy between visit V1 and V2, followed by
a steeper decrease after delivery.
Ethnic Background
PLS-DA using a dummy matrix of ethnic background categories
(excluding the very small number of South Americans) was carried
out at the three visits and resulted in overall significant models.
However, a closer inspection of the cross-validated predictions (see
Table 5) revealed that this was mostly driven by the samples from
participants with Western background, and potentially South
Asians. According to the PLS loading weights, formate, alanine
and the combined lactate and threonine variable contributed most
to the models, along with 3-hydroxyisovalerate, 1,6-anhydroglu-
cose and an unidentified compound at 0.55 ppm. Note that the
latter was also observed above with respect to the progression of
pregnancy.
Using the categories ‘‘Western’’, ‘‘South Asian’’ and ‘‘Other’’,
follow-up ANOVAs were performed on all concentration variables
at all visits. Significant results are shown in Table 6.
Finally, the previous ANOVAs with respect to GDM according
to the graded classes were repeated separately for the aforemen-
tioned three ethnic categories. Compared to Table 4, the results
became less reliable: Only in the South Asian category did the
increase in glucose (visit V1 and V2) as well as citrate and the
unknown signal at 1.08 ppm (both at visit V2) remain significant.
None of the variables reached significance in the other two ethnic
categories. Nonetheless, the mean citrate concentration exhibited
the same association with the graded classes, i.e. the presence and
severity of hyperglycemia, and the increase-decrease pattern as
described above for the combined data set.
Discussion
Although its primary aim was the detection of patterns in the
urinary metabolome related to GDM, the most immediate finding
of the metabolomics efforts that are part of the STORK
Groruddalen cohort study is that the changes of the composition
of urine during and after pregnancy are substantial enough to
clearly differentiate between sampling time points.
The most prominent developments were the steady increase of
urinary lactose, and the increase-decrease pattern of a number of
NMR signals between 0.55 and 1.10 ppm. Resonances in this
region have sometimes been associated with bile acids [46,47], but
our own spike-in experiments (data not shown) failed to confirm
this. Spectral simulations using the online tools at nmrdb.org
[48,49] suggest that these signals may belong to pregnanediol and
estrogens, or more likely their water-soluble sulfates and glucuro-
nides.
Table 3. Selected substances and signals differing between the WHO classes (healthy, diabetes) at visits V1 and V2.
Median concentration (IQR) [mM/mM Creatinine] t-test
Visita Compound WHO: healthy WHO: GDM p-value
V1 Citrate 0.23 (0.18–0.29) 0.28 (0.19–0.34) 2e-4 (q)
Unknown doublet, 1.08 ppmx 3.4 (2.2–4.8) 4 (2.5–6.4) 0.007 (q)
Unknown doublet, 1.11 ppmx 11 (7.5–15) 14 (8.9–18) 9e-4 (q)
V2 Citrate 0.24 (0.17–0.31) 0.3 (0.22–0.4) 7e-5 (q)
Unknown doublet, 1.08 ppmx 5.4 (3.5–7.9) 5.6 (4.2–10) 0.01 (q)
Unknown doublet, 1.11 ppmx 19 (14–25) 24 (17–29) 0.001 (q)
aVisit V1: gestational week 8–20; V2: gestational week 26–30.
xConcentrations of unidentified signals in arbitrary units, but nonetheless normalized to creatinine.
doi:10.1371/journal.pone.0052399.t003
Table 2. Cont.
Median concentrationa (IQR) [mM/mM Creatinine] Rel. individual FCa (t-test p-value)
Compound Visit V1b (,20 wk) Visit V2b (28 wk) Visit V3b (3 mo p.p.) V1 R V2 V2 R V3
Acetaminophen sulfatee 0.03 (0.023–0.039) 0.033 (0.025–0.042) 0.03 (0.023–0.04) 1.09 (0.00011) 21.01 (0.72)
Hippurate 0.21 (0.13–0.32) 0.22 (0.14–0.33) 0.23 (0.14–0.36) 1.02 (0.49) 1.01 (0.68)
Histidine regiong 0.058 (0.052–0.065) 0.068 (0.061–0.075) 0.053 (0.048–0.06) 1.17 (1.2e-76) 21.26 (6.3e-101)
Formate 0.035 (0.026–0.052) 0.052 (0.038–0.073) 0.016 (0.011–0.025) 1.51 (1.9e-59) 23.28 (3.4e-147)
aWhile the median (IQR) values are reported on their natural scale, all parametric statistical tests were carried out using the log-transformed, normally distributed
variables.
bVisit V1: gestational week 8–20; V2: gestational week 26–30; V3:10–16 weeks post partum.
cUrea is affected by NMR water suppression.
dBroader spectral signal; measured before subtracting BXR baseline.
eCompound very dilute to undetectable in a substantial number of samples; reported concentration may represent noise.
fConcentration of creatinine is reported as absolute mM before normalization.
gNo conclusive identification, quantified as stated.
xConcentrations of unidentified signals in arbitrary units, but nonetheless individually normalized to creatinine.
doi:10.1371/journal.pone.0052399.t002
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Figure 4. Citrate concentration and relative change during and after pregnancy, by degree of hyperglycemia. Median concentration
(695% CI of the median as dashed lines) of urine citrate concentration relative to creatinine levels at the three visits (V1: gestational week 8–20; V2:
gestational week 26–30; V3:10–16 weeks post partum), shown separately in red, green and blue, respectively, for the three graded classes based on
modified IADPSG definitions and the HAPO study (G0: healthy, normoglycemic; G1: GDM with relatively mild hyperglycemia; G2: GDM with more
pronounced hyperglycemia). Insets show the mean patient-wise relative fold-change (695% CI of the mean, based on log values) between visits V1
and V2 (panel A), and V2 and V3 (panel B), respectively. Note the sharper rise and subsequent fall of urinary citrate associated with the severity of
GDM.
doi:10.1371/journal.pone.0052399.g004
Table 4. Selected substances and signals differing between the three graded classes (healthy, GDM with mild hyperglycemia,
GDM with pronounced hyperglycemia) at visits V1 and V2.
Median concentration (IQR) [mM/mM Creatinine] ANOVA
Visita Compound healthy (G0)b GDM, mild (G1)b GDM (G2)b p-value
V1 Glucose 0.1 (0.078–0.13) 0.1 (0.083–0.14) 0.13 (0.096–0.19) 6e-6
Lysine 0.019 (0.01–0.031) 0.025 (0.012–0.039) 0.026 (0.018–0.044) 4e-4
Citrate 0.23 (0.18–0.29) 0.24 (0.17–0.32) 0.29 (0.21–0.38) 0.04
Unknown doublet, 1.08 ppmx 3.3 (2.1–4.7) 3.9 (2.5–5.2) 4.4 (2.9–6.8) 9e-4
Unknown doublet, 1.11 ppmx 11 (7.6–15) 12 (8.1–17) 14 (9.1–15) 0.01
V2 Glucose 0.14 (0.11–0.18) 0.14 (0.1–0.19) 0.18 (0.15–0.27) 6e-6
Citrate 0.24 (0.17–0.31) 0.26 (0.19–0.34) 0.35 (0.29–0.45) 3e-5
Unknown doublet, 1.08 ppmx 5.3 (3.4–7.7) 5.6 (4–8.4) 7.8 (4.5–13) 2e-4
Unknown doublet, 1.11 ppmx 19 (14–25) 19 (15–26) 21 (16–30) 0.03
aVisit V1: gestational week 8–20; V2: gestational week 26–30.
bClassification by graded criteria based on modified IADPSG definitions and the HAPO study: Healthy, normoglycemic (G0); GDM with relatively mild hyperglycemia (G1)
or with more pronounced hyperglycemia (G2). Thresholds are defined in the Materials section.
xConcentrations of unidentified signals in arbitrary units, but nonetheless normalized to creatinine.
doi:10.1371/journal.pone.0052399.t004
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The general increase of lactose is a well-known phenomenon
and is linked to lactation and the prolactin levels in blood.
Appreciable lactose concentrations in urine are usually first
observed at the end of the second trimester, between gestational
week 20 and 28, followed by a steady increase over the remainder
of the pregnancy and another sharp rise in the days after delivery.
[50,51] However, Fig. 3 clearly shows that a number of
participants did in fact have lower urinary lactose concentrations
post partum (visit V3) than during pregnancy (visit V1 and
particularly visity V2). It remains to be determined at a later stage
whether this can be correlated to e.g. breastfeeding habits.
Besides lactose and the presumed hormones, many other
concentration variables showed statistically significant develop-
ments between the visits. However, since the absolute creatinine
concentration, which was used for normalization, varied by 20–
30% between visits it is not clear which of the smaller changes are
specific to pregnancy and which are due to dilution effects.
Nonetheless, it is common clinical practice to relate analyte
concentrations in individual urine samples to creatinine, and thus
doing so facilitates the comparison of our findings with other
reports. [52,53] In pregnancy research in particular, this issue has
been brought up in relation with albumin measurements, where
the use of creatinine as a reference was deemed appropriate. [54]
It has also been reported that the overall creatinine excretion over
a 24-h period does not significantly change in pregnancy, further
supporting the case for normalization. [55] Finally, even if one
were to dismiss variations in metabolite concentrations below
30%, a number of compounds and signals still rise above this
threshold, among them the increase and subsequent decrease of
alanine and the combined threonine and lactate signal, and the
decrease of glycine, tyrosine and formate after birth. [14,17].
The metabolomics approach has been previously applied in
pregnancy research and has successfully identified biomarker
candidates [28], however, many studies used more sensitive mass
spectrometry platforms instead of NMR. Examples include an
improved prediction of pre-eclampsia [56–58] or low birth weight
Table 5. PLS-DA validation results for dummy matrices of
ethnic background at the three visits.
Groupa Visit
Q2, R2 at
6 comp. NMC, permutation test at 6 comp.
West V1 0.305/0.392 69 (63–74)/161 (150–174)
V2 0.330/0.410 77 (73–83)/165 (150–179)
V3 0.317/0.404 77 (72–82)/138 (126–146)
S.Asiab V1 0.108/0.270 109 (105–116)/122 (111–130)
V2 0.112/0.242 122 (118–126)/121 (114–130)
V3 0.210/0.315 90 (85–95)/105 (97–113)
E.Asiac V1 0.087/0.149 37/35 (32–37)
V2 0.087/0.162 31/30 (26–31)
V3 0.066/0.113 34/32 (29–34)
ME.CA.NA.d V1 0.027/0.100 102/85 (80–91)
V2 0.066/0.164 99 (97–100)/87 (80–94)
V3 0.038/0.149 84 (83–85)/73 (67–78)
Sub-Sahara V1 0.036/0.098 52/48 (45–52)
V2 0.062/0.112 48/44 (41–47)
V3 0.045/0.128 37/35 (32–37)
aExcluding South America, n = 12.
bS.Asia: South Asia;
cE.Asia: East Asia;
dME.CA.NA.: Middle East, Central Asia and North Africa.
doi:10.1371/journal.pone.0052399.t005
Table 6. Selected substances and signals differing between categories of ethnic background at visits V1 through V3.
Median concentration (IQR) [mM/mM Creatinine] ANOVA
Visit Compound West South Asia All Others p-value
V1 Formate 0.03 (0.024–0.04) 0.04 (0.028–0.059) 0.043 (0.029–0.061) 2e-9
Alanine 0.034 (0.027–0.047) 0.045 (0.032–0.065) 0.044 (0.031–0.058) 5e-8
3-Hydroxyisovalerate 0.008 (0.0062–0.011) 0.01 (0.0075–0.013) 0.01 (0.0079–0.013) 2e-8
1,6-Anhydroglucose 0.0035 (0.002–0.009) 0.003 (0.002–0.006) 0.002 (0.001–0.004) 6e-8
Lactate/Threoninex 25 (17–34) 34 (23–57) 36 (23–55) 4e-12
Unknown multiplet, 0.55 ppmx 2.1 (1.8–2.5) 2.4 (1.9–3.1) 2.5 (2–3.1) 7e-9
V2 Formate 0.043 (0.034–0.058) 0.061 (0.042–0.08) 0.066 (0.046–0.094) 1e-20
Alanine 0.059 (0.042–0.08) 0.073 (0.051–0.093) 0.069 (0.047–0.1) 1e-5
3-Hydroxyisovalerate 0.0094 (0.008–0.012) 0.012 (0.01–0.016) 0.012 (0.01–0.015) 3e-12
1,6-Anhydroglucose 0.006 (0.0032–0.012) 0.004 (0.002–0.007) 0.004 (0.002–0.007) 8e-6
Lactate/Threoninex 49 (36–70) 64 (42–90) 62 (43–93) 3e-6
Unknown multiplet, 0.55 ppmx 4.5 (3.9–5.4) 5.4 (4.3–6.4) 5.3 (4.4–6.6) 5e-10
V3 Formate 0.013 (0.0093–0.019) 0.02 (0.014–0.029) 0.02 (0.013–0.029) 2e-11
Alanine 0.016 (0.013–0.023) 0.024 (0.019–0.031) 0.022 (0.017–0.031) 8e-14
3-Hydroxyisovalerate 0.0048 (0.003–0.007) 0.006 (0.004–0.008) 0.006 (0.004–0.008) 3e-6
1,6-Anhydroglucose 0.0041 (0.0017–0.01) 0.003 (0.001–0.006) 0.003 (0.001–0.005) 2e-6
Lactate/Threoninex 6.9 (4.7–11) 9.8 (7.3–14) 11 (7.1–15) 5e-11
Unknown multiplet, 0.55 ppmx 1.5 (1.2–2) 1.9 (1.4–2.3) 1.8 (1.4–2.3) 5e-4
xConcentrations of the unidentified signal and the combined lactate and threonine variable in arbitrary units, but nonetheless normalized to creatinine.
doi:10.1371/journal.pone.0052399.t006
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[59]. An exploratory study by Diaz et al. [29] profiled second-
trimester maternal urine and plasma from several dozen partic-
ipants with respect to several endpoints including gestational
diabetes. Among others, they observed elevated levels of 3-
hydroxyisovalerate and 2-hydroxyisobutyrate and an unassigned
doublet signal at 1.10 ppm. Allowing for small shift variations, the
latter may coincide with the doublets at 1.08 or 1.11 ppm in our
study, whereas the former two only exhibited an insignificant
increase in our material. However, in a follow-up analysis using
untargeted UPLC-MS the same researchers reported no signifi-
cant correlations with GDM [60], and neither of the studies found
the elevated concentrations of citrate that we discovered.
In a broader perspective, type 1 and 2 diabetes have been
studied rather extensively. [61] Profiling urine samples by NMR,
Salek et al. studied T2DM in db/db mice, Zucker rats and
unmedicated human patients. [24] The mouse and rat samples
yielded highly significant multivariate classification models, with
disease-correlated increases of urinary citrate, DMA and lactate.
The human urine samples had a much larger intra-group
variation, but nonetheless a significant increase of citrate, DMA,
lactate and several amino acids was observed in the diabetes
patients.
Most pertinent to our own work, perhaps, are the studies by
Zhao et al. [62] and Zhang et al. [63], which addressed pre-
diabetic states and the progression of glucose intolerance,
respectively. The former succeeded in identifying patients with
impaired glucose tolerance using untargeted UPLC-qTOF mass
spectrometry of plasma and urine samples. The urine samples
performed worse than plasma, but nonetheless led to a predictive
PLS-DA model. Of the compounds involved, only hippurate and
phenylacetyl-glutamine were visible in our NMR spectra, and we
did not observe a decrease as described by Zhao et al. The Zhang
study [63] could differentiate between healthy subjects and overt
T2DM cases using NMR spectra of plasma, but could not identify
the milder cases with impaired glucose regulation.
It has also been reported previously that ethnic and geographic
background can have a large effect on the urinary excretion profile
as measured by NMR. [64] As part of the INTERMAP study, a
multivariate discriminant analysis could correctly classify over
95% of several hundred urine samples from the United States,
Japan and southern China, respectively. Our material, lacking the
geographic distribution, showed far less predictive power, indicat-
ing that ethnic background had only a comparably subtle impact
on the urine profiles. It appears that in terms of ‘‘nature vs.
nurture’’, the urine metabolome seems to be determined more by
immediate lifestyle and diet than by genes. Regarding GDM, re-
analyzing the concentration variables within the separate ethnic
categories reproduced roughly the same mean values as the
complete data set, but probably due to the lower number of
participants in the respective categories most of these did not reach
statistical significance.
NMR-based metabolomics has demonstrated only limited
usefulness in the study of a condition with, in the majority of
cases, only mild metabolic changes, and several factors aggravate
the situation: Even though NMR profiling has a high reproduc-
ibility even across laboratories, is non-selective, non-targeted and
yet quantitative, its lower sensitivity compared to mass spectrom-
etry means that only a subset of the metabolome can be surveyed.
Furthermore, disease-associated concentration changes –or pat-
terns thereof– must be larger than unrelated intra-individual and
intra-group variations in order to be recognized by univariate or
multivariate statistical methods. The type of study influences the
amount of such variations: Case-control or animal studies, for
example, typically aim for a high degree of homogeneity which
facilitates biomarker detection but may limit their generalizability.
Our material from a cohort study, on the other hand, gives a more
realistic representation of the population at large but consequently
contains more biological variation. The fact that urine also
exhibits stronger variations in ionic strength than other matrices,
leading to noise in the form of peak shift variations, does not
simplify matters. We addressed this complication by primarily
working with a matrix of concentrations instead of the raw spectra.
Note, however, that all multivariate analyses also were carried out
on the spectra. They never outperformed the matrix (data not
shown). Apart from analytical difficulties, two opposing effects
present challenges to the detection of disease states from urine:
While diurnal and dietary variation may increase individual
variation that is unrelated to the hypothesis being tested, the
body’s homeostasis and renal regulation may mask the impact of
the disease on the excretion profile. [65–67] It seems to be a
common observation that studies analyzing both plasma and urine
in parallel, see above, find the former to be correlate better with
the disease phenotype. [29,62].
Note, however, that all these considerations do not categorically
invalidate urinary NMR metabolomics. The robustness and ease
of use of NMR and in particular the non-invasive nature of urine
sampling makes this approach attractive. And while, by its very
definition, the search for biomarkers cannot guarantee positive
results, the successful classification of the three visits clearly
demonstrates that this is possible even in the face of the adverse
influences listed above.
Conclusion
The immediate result of the present study is that urine-based
NMR metabolomics can differentiate between time points during
and after pregnancy and thus track its development, but that it
could not identify reliable biomarkers for gestational diabetes
mellitus (GDM) in a large, multiethnic population: The pattern of
urinary metabolites, at least above micromolar concentrations, is
not influenced strongly and consistently enough by the condition.
Nonetheless, an increase of excreted citrate correlated with the
severity of GDM was observed, that was consistent with earlier
findings.
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